Callan Family Office LLC Purchases Shares of 821 Waters Co. (NYSE:WAT)

Callan Family Office LLC purchased a new position in Waters Co. (NYSE:WAT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 821 shares of the medical instruments supplier's stock, valued at approximately $305,000.

A number of other large investors also recently modified their holdings of the business. QRG Capital Management Inc. acquired a new stake in shares of Waters in the 3rd quarter worth approximately $208,000. Assetmark Inc. increased its position in shares of Waters by 16.5% during the 3rd quarter. Assetmark Inc. now owns 1,200 shares of the medical instruments supplier's stock valued at $432,000 after purchasing an additional 170 shares during the period. Atria Investments Inc raised its stake in shares of Waters by 10.3% in the 3rd quarter. Atria Investments Inc now owns 3,141 shares of the medical instruments supplier's stock worth $1,130,000 after buying an additional 294 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Waters during the third quarter valued at about $35,000. Finally, Kennebec Savings Bank acquired a new position in Waters during the third quarter worth about $33,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on WAT shares. UBS Group boosted their target price on shares of Waters from $405.00 to $410.00 and gave the stock a "neutral" rating in a report on Thursday, February 13th. Barclays upgraded Waters from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $360.00 to $415.00 in a research report on Monday, February 10th. StockNews.com downgraded Waters from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Scotiabank upgraded Waters from a "sector perform" rating to a "sector outperform" rating and boosted their price objective for the stock from $430.00 to $450.00 in a report on Thursday, February 13th. Finally, Wells Fargo & Company raised their target price on shares of Waters from $415.00 to $420.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Eleven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $391.07.

Remove Ads

Waters Stock Down 0.2 %

Shares of Waters stock traded down $0.74 during trading on Thursday, hitting $372.39. 69,127 shares of the stock traded hands, compared to its average volume of 437,861. The stock has a market cap of $22.12 billion, a P/E ratio of 34.84, a PEG ratio of 3.79 and a beta of 1.00. The company has a fifty day moving average price of $391.20 and a two-hundred day moving average price of $369.80. Waters Co. has a twelve month low of $279.24 and a twelve month high of $423.56. The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.65 and a current ratio of 0.94.

Waters (NYSE:WAT - Get Free Report) last posted its earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. Equities research analysts predict that Waters Co. will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.